Balcinrenone (AZD9977), an MR modulator that showed organ protection capabilities without affecting urinary sodium/potassium ratio in animal models [138], is currently being evaluated vs placebo in the Phase IIb RCT MIRACLE, enrolling 147 patients with heart failure and CKD (NCT04595370). Here, NR3C2 is linked to heart failure.